|

Etoricoxib in Patients With Parkinsonian Disease

RECRUITINGPhase 2Sponsored by Ihab Elsayed Hassan
Actively Recruiting
PhasePhase 2
SponsorIhab Elsayed Hassan
Started2026-01-30
Est. completion2027-11-10
Eligibility
Age50 Years – 70 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07370532

Summary

Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).

Eligibility

Age: 50 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age ≥ 18 years.
* Both male and female will be included.
* Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.

Exclusion Criteria:

* Breast feeding
* Patients with significant liver and kidney function abnormalities.
* Alcohol and / or drug abusers.
* Patients with known allergy to the study medications
* Pregnant women and women with planned pregnancy.
* Patients who are currently using other anti-inflammatory drugs.

Conditions2

Parkinson DiseaseParkinson's Disease

Interventions2

EtoricoxibL-dopa

Browse More Trials

Parkinson's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.